Ansbert Gadicke Sells 140,488 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 140,488 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $171,395.36. Following the completion of the transaction, the insider owned 6,007,122 shares in the company, valued at $7,328,688.84. The trade was a 2.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total value of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $208,072.00.
• On Tuesday, October 28th, Ansbert Gadicke sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total value of $113,271.52.
• On Monday, October 27th, Ansbert Gadicke sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total value of $125,059.48.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL traded down $0.02 during mid-day trading on Thursday, reaching $1.20. The stock had a trading volume of 647,728 shares, compared to its average volume of 891,846. The business’s 50 day moving average price is $1.61 and its 200 day moving average price is $1.32. The company has a current ratio of 3.87, a quick ratio of 5.30 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.41. The company has a market cap of $58.25 million, a P/E ratio of -0.74 and a beta of 0.72.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. Research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HOWL. Quadrature Capital Ltd bought a new position in Werewolf Therapeutics in the second quarter worth approximately $28,000. Vontobel Holding Ltd. bought a new position in Werewolf Therapeutics in the first quarter worth approximately $34,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the second quarter worth approximately $48,000. Nuveen LLC bought a new position in Werewolf Therapeutics in the first quarter worth approximately $71,000. Finally, AQR Capital Management LLC bought a new position in Werewolf Therapeutics in the first quarter worth approximately $79,000. Institutional investors own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HOWL. JMP Securities reduced their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Bank of America reduced their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.